Pharmacielo Ltd (PCLO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pharmacielo Ltd (PCLO) has a cash flow conversion efficiency ratio of 0.236x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-3.53 Million ≈ $-2.55 Million USD) by net assets (CA$-14.94 Million ≈ $-10.81 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pharmacielo Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Pharmacielo Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Pharmacielo Ltd (PCLO) financial obligations for a breakdown of total debt and financial obligations.
Pharmacielo Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pharmacielo Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Axiom Properties Ltd
AU:AXI
|
-0.145x |
|
LabGenomics Co. Ltd
KQ:084650
|
-0.034x |
|
Eurasia Fonciere Investissements Société Anonyme
PA:EFI
|
-0.015x |
|
Hemostemix Inc
V:HEM
|
0.839x |
|
Airway
WAR:AWM
|
1.059x |
|
Bhandari Hosiery Exports Limited
NSE:BHANDARI
|
0.018x |
|
Falmaco Nonwoven Industri PT Tbk
JK:FLMC
|
-0.007x |
|
Ladangbaja Murni PT Tbk
JK:LABA
|
-0.054x |
Annual Cash Flow Conversion Efficiency for Pharmacielo Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Pharmacielo Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see PCLO market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$-7.52 Million ≈ $-5.44 Million |
CA$-1.97 Million ≈ $-1.42 Million |
0.262x | -91.45% |
| 2023-12-31 | CA$-1.68 Million ≈ $-1.22 Million |
CA$-5.15 Million ≈ $-3.73 Million |
3.066x | +301.87% |
| 2022-12-31 | CA$6.39 Million ≈ $4.62 Million |
CA$-9.71 Million ≈ $-7.02 Million |
-1.519x | -46.22% |
| 2021-12-31 | CA$19.33 Million ≈ $13.98 Million |
CA$-20.07 Million ≈ $-14.52 Million |
-1.039x | -20.82% |
| 2020-12-31 | CA$26.25 Million ≈ $18.99 Million |
CA$-22.56 Million ≈ $-16.32 Million |
-0.860x | -55.33% |
| 2019-12-31 | CA$45.47 Million ≈ $32.89 Million |
CA$-25.16 Million ≈ $-18.20 Million |
-0.553x | -30.88% |
| 2018-12-31 | CA$185.55K ≈ $134.23K |
CA$-78.47K ≈ $-56.76K |
-0.423x | +98.98% |
| 2017-12-31 | CA$91.02K ≈ $65.84K |
CA$-3.79 Million ≈ $-2.74 Million |
-41.637x | -12744.15% |
| 2016-12-31 | CA$9.57 Million ≈ $6.92 Million |
CA$-3.10 Million ≈ $-2.24 Million |
-0.324x | -- |
About Pharmacielo Ltd
PharmaCielo Ltd., together with its subsidiary, engages in cultivating, processing, and supplying medicinal-grade cannabis extracts in Canada. The company's products include medicinal-grade dried cannabis flower, cannabis oil extracts, tetrahydrocannabinol and cannabidiol medical cannabis, and other cannabis related products, as well as provides telemedicine software. The company also exports its… Read more